% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Bakker:165605,
author = {Bakker, Wineke and Imbernon, Monica and Salinas, Casper
Gravesen and Moro Chao, Daniela Herrera and Hassouna, Rim
and Morel, Chloe and Martin, Claire and Leger, Caroline and
Denis, Raphael G P and Castel, Julien and Peter, Andreas and
Heni, Martin and Maetzler, Walter and Nielsen, Heidi Solvang
and Duquenne, Manon and Schwaninger, Markus and Lundh, Sofia
and Johan Hogendorf, Wouter Frederic and Gangarossa,
Giuseppe and Secher, Anna and Hecksher-Sørensen, Jacob and
Pedersen, Thomas Åskov and Prevot, Vincent and Luquet,
Serge},
title = {{A}cute changes in systemic glycemia gate access and action
of {GLP}-1{R} agonist on brain structures controlling energy
homeostasis.},
journal = {Cell reports},
volume = {41},
number = {8},
issn = {2211-1247},
address = {[New York, NY]},
publisher = {Elsevier},
reportid = {DZNE-2022-01738},
pages = {111698},
year = {2022},
abstract = {Therapies based on glucagon-like peptide-1 (GLP-1)
long-acting analogs and insulin are often used in the
treatment of metabolic diseases. Both insulin and GLP-1
receptors are expressed in metabolically relevant brain
regions, suggesting a cooperative action. However, the
mechanisms underlying the synergistic actions of insulin and
GLP-1R agonists remain elusive. In this study, we show that
insulin-induced hypoglycemia enhances GLP-1R agonists entry
in hypothalamic and area, leading to enhanced whole-body fat
oxidation. Mechanistically, this phenomenon relies on the
release of tanycyctic vascular endothelial growth factor A,
which is selectively impaired after calorie-rich diet
exposure. In humans, low blood glucose also correlates with
enhanced blood-to-brain passage of insulin, suggesting that
blood glucose gates the passage other energy-related signals
in the brain. This study implies that the preventing
hyperglycemia is important to harnessing the full benefit of
GLP-1R agonist entry in the brain and action onto lipid
mobilization and body weight loss.},
keywords = {Humans / Blood Glucose: metabolism / Vascular Endothelial
Growth Factor A: metabolism / Glucagon-Like Peptide 1:
metabolism / Insulin: metabolism / Homeostasis / Brain:
metabolism / CP: Metabolism (Other) / brain access (Other) /
diabetes (Other) / glucagon-like peptide 1 analogs (Other) /
glycemic control (Other) / metabolism (Other) / nutrient
partitioning (Other) / obesity (Other) / tanycyte (Other) /
Blood Glucose (NLM Chemicals) / Vascular Endothelial Growth
Factor A (NLM Chemicals) / Glucagon-Like Peptide 1 (NLM
Chemicals) / Insulin (NLM Chemicals)},
cin = {AG Maetzler},
ddc = {610},
cid = {I:(DE-2719)5000024},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
pmc = {pmc:PMC9715912},
pubmed = {pmid:36417883},
doi = {10.1016/j.celrep.2022.111698},
url = {https://pub.dzne.de/record/165605},
}